ROVI updates its strategy in a meeting with shareholders, investors and analysts
Tue, 16/11/2021 - 14:31
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Related
ROVI reports operating revenue growth of 24% and EBITDA growth of 25%
• Operating revenue increased by 24% to 575.5 million euros driven...
3 min
04/11/2022
On his visit to the plant, which is ready to start production as soon as the authorisation from the Spanish Agency of Medicines and...
4 min
24/10/2022
Glicopepton Biotech founded to produce compounds of high technological value
· ROVI, Càrniques Celrà and Grupo Costa announce...
3 min
04/10/2022
shutterstock_1323088832.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 16 November 2021
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold a virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.